METABOLISMO ÓSEO, VASCULAR, ENFERMEDADES INFLAMATORIAS CRÓNICAS Y BIOMARCADORES
METOSEO
Complejo Asistencial Universitario de León
León, EspañaPublicaciones en colaboración con investigadores/as de Complejo Asistencial Universitario de León (10)
2020
-
Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease
Clinical Kidney Journal, Vol. 13, Núm. 6, pp. 1017-1024
-
Collaborative hospital models for shared care and on-demand interconsultations. Which offer the best results for Orthopaedic Surgery and Trauma?
Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 167-173
2019
-
Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort
Frontiers in Genetics, Vol. 10, Núm. FEB
2017
-
Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study
Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 513-520
2015
-
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
Nephrology Dialysis Transplantation, Vol. 30, Núm. 7, pp. 1176-1185
-
The concordance between patients' renal replacement therapy choice and definitive modality: Is it a utopia?
PLoS ONE, Vol. 10, Núm. 10
2008
-
Angiographic correlates of the treadmill scores in non-high-risk patients with unstable angina
Cardiology, Vol. 109, Núm. 1, pp. 1-9
2006
-
Comparación angiográfica de los criterios e índices de alto riesgo para ergometría convencional en pacientes diagnosticados de angina inestable en función del sexo, la edad o el uso de fármacos bradicardizantes
Revista Espanola de Cardiologia, Vol. 59, Núm. 5, pp. 448-457
-
Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial
Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326
2003
-
Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage
Clinical Endocrinology, Vol. 58, Núm. 4, pp. 471-481